Quarterly report · Q1
4572.TEDINET S100QP76
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥227m | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥555m | 2022-01-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | −¥506m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥1m | 2022-01-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥513m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5m | 2022-01-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | −¥514m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥11m | 2022-01-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥519m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥15m | 2022-01-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥4.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2022-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥547m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.5bn | at 2022-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-32.78 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.12 | 2022-01-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 88.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥570m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥227m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥64m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥286m |
| jpcrp040300-q1r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | −¥108m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-03-31 | ¥269m |
| jpcrp040300-q1r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-03-31 | ¥109m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 304
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |